Shares of Neon Therapeutics Inc (NASDAQ:NTGN) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $19.33.
Several analysts have issued reports on NTGN shares. Berenberg Bank started coverage on Neon Therapeutics in a research note on Wednesday, March 27th. They issued a “buy” rating and a $15.00 price target on the stock. Zacks Investment Research downgraded Neon Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th.
Neon Therapeutics stock traded down $0.28 during mid-day trading on Friday, hitting $5.30. 282 shares of the company’s stock were exchanged, compared to its average volume of 80,397. The company has a market capitalization of $153.27 million and a PE ratio of -0.98. Neon Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $16.23.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.03). Equities research analysts predict that Neon Therapeutics will post -2.74 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Oxford Asset Management LLP bought a new position in shares of Neon Therapeutics in the 1st quarter valued at about $549,000. ArrowMark Colorado Holdings LLC grew its holdings in shares of Neon Therapeutics by 4.9% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 947,295 shares of the company’s stock valued at $6,120,000 after acquiring an additional 44,434 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Neon Therapeutics by 153.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 30,308 shares of the company’s stock valued at $196,000 after acquiring an additional 18,328 shares in the last quarter. Marshall Wace North America L.P. bought a new position in shares of Neon Therapeutics in the 1st quarter valued at about $49,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Neon Therapeutics by 144.9% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 134,593 shares of the company’s stock valued at $869,000 after acquiring an additional 79,639 shares in the last quarter. 70.50% of the stock is currently owned by hedge funds and other institutional investors.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.